SCHEMBL16481705

SCHEMBL16481705

Cc1nc(Nc2ccnc(F)c2)nc(N[C@@H]2C[C@H](CO)[C@@H](O)[C@H]2O)c1-c1nc2ccccc2s1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ IRAK4 Q9NWZ3 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16482046 0.92 IRAK4 (0.85) IRAK4
SCHEMBL12038447 0.90 IRAK4 (0.85) IRAK4
SCHEMBL16481686 0.89 IRAK4 (1.00) IRAK4
SCHEMBL12038478 0.89 IRAK4 (0.85) IRAK4
SCHEMBL12038460 0.88 IRAK4 (0.86) IRAK4
SCHEMBL12038409 0.88 IRAK4 (0.89) IRAK4
SCHEMBL12038463 0.87 IRAK4 (0.86) IRAK4
SCHEMBL17184224 0.87 IRAK4 (1.00) IRAK4
SCHEMBL16481629 0.87 IRAK4 (1.00) IRAK4
SCHEMBL16482197 0.87 IRAK4 (1.00) IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2903617-B1 INHIBITORS OF IRAK4 ACTIVITY MERCK SHARP & DOHME (US) 2019-01-30 — — EP claimed
US-9598440-B2 Inhibitors of IRAK4 activity MERCK SHARP & DOHME CORP. (US) 2017-03-21 — — US claimed
US-20150299224-A1 INHIBITORS OF IRAK4 ACTIVITY MERCK SHARP & DOHME CORP. (US) 2015-10-22 — — US claimed
EP-2903617-B1 INHIBITORS OF IRAK4 ACTIVITY MERCK SHARP & DOHME (US) 2019-01-30 — — EP disclosed
EP-2903617-B1 INHIBITORS OF IRAK4 ACTIVITY MERCK SHARP & DOHME (US) 2019-01-30 — — EP disclosed
US-9598440-B2 Inhibitors of IRAK4 activity MERCK SHARP & DOHME CORP. (US) 2017-03-21 — — US disclosed
US-9598440-B2 Inhibitors of IRAK4 activity MERCK SHARP & DOHME CORP. (US) 2017-03-21 — — US disclosed
US-9598440-B2 Inhibitors of IRAK4 activity MERCK SHARP & DOHME CORP. (US) 2017-03-21 — — US disclosed
US-20150299224-A1 INHIBITORS OF IRAK4 ACTIVITY MERCK SHARP & DOHME CORP. (US) 2015-10-22 — — US disclosed
US-20150299224-A1 INHIBITORS OF IRAK4 ACTIVITY MERCK SHARP & DOHME CORP. (US) 2015-10-22 — — US disclosed
US-20150299224-A1 INHIBITORS OF IRAK4 ACTIVITY MERCK SHARP & DOHME CORP. (US) 2015-10-22 — — US disclosed
WO-2014058685-A1 INHIBITORS OF IRAK4 ACTIVITY MERCK SHARP & DOHME CORP. (US) 2014-04-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299224-A1 INHIBITORS OF IRAK4 ACTIVITY IRAK4, IRAK1, IRAK2 IRAK4 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback